Limits...
ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.

Kim CY, Seo SH, An MS, Kim KH, Bae KB, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH - Ann Coloproctol (2015)

Bottom Line: ERCC1-positive expression was statistically significant in the older patients (P = 0.032).In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397).The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

ABSTRACT

Purpose: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.

Methods: A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.

Results: ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

Conclusion: We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus

Five-year disease-free survival rate of stage III patients. ERCC, excision repair cross-complementation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4496459&req=5

Figure 3: Five-year disease-free survival rate of stage III patients. ERCC, excision repair cross-complementation.

Mentions: The 5-year DFS rate was 66.38% in the ERCC1-negative group and 71.16% in the ERCC1-positive group (P = 0.396) (Fig. 2). The 5-year DFS rate for patients with stage III disease was not significantly different between the two groups (64.85% in the negative group and 67.50% in the positive group, P = 0.582) (Fig. 3). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients or in those with stage III disease. According to the univariate analysis, the prognostic factors for DFS were female sex (P = 0.047), N stage (P = 0.002), elevated preoperative CEA level (P = 0.008), and elevated postoperative CEA level (P < 0.001). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative CEA level (P = 0.001) (Table 2). However, ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P =0.397) (Table 2).


ERCC1 as a Predictive Marker for FOLFOX Chemotherapy in an Adjuvant Setting.

Kim CY, Seo SH, An MS, Kim KH, Bae KB, Hwang JW, Kim JH, Kim BM, Kang MS, Oh MK, Hong KH - Ann Coloproctol (2015)

Five-year disease-free survival rate of stage III patients. ERCC, excision repair cross-complementation.
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4496459&req=5

Figure 3: Five-year disease-free survival rate of stage III patients. ERCC, excision repair cross-complementation.
Mentions: The 5-year DFS rate was 66.38% in the ERCC1-negative group and 71.16% in the ERCC1-positive group (P = 0.396) (Fig. 2). The 5-year DFS rate for patients with stage III disease was not significantly different between the two groups (64.85% in the negative group and 67.50% in the positive group, P = 0.582) (Fig. 3). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients or in those with stage III disease. According to the univariate analysis, the prognostic factors for DFS were female sex (P = 0.047), N stage (P = 0.002), elevated preoperative CEA level (P = 0.008), and elevated postoperative CEA level (P < 0.001). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative CEA level (P = 0.001) (Table 2). However, ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P =0.397) (Table 2).

Bottom Line: ERCC1-positive expression was statistically significant in the older patients (P = 0.032).In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397).The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

View Article: PubMed Central - PubMed

Affiliation: Department of Surgery, Inje University Busan Paik Hospital, Inje University College of Medicine, Busan, Korea.

ABSTRACT

Purpose: The purpose of this study was to identify the excision repair cross-complementation group 1 (ERCC1) as a predictive marker for FOLFOX adjuvant chemotherapy in stages II and III colon cancer patients.

Methods: A total of 166 high risk stages II and III colon cancer patients were retrospectively enrolled in this study, and data were collected prospectively. They underwent a curative resection followed by FOLFOX4 adjuvant chemotherapy. We analyzed ERCC1 expression in the primary colon tumor by using immunohistochemical staining. The oncological outcomes included the 5-year disease-free survival (DFS) rate. The DFS was analyzed by using the Kaplan-Meier method with the log-rank test. A Cox proportional hazard model was used for the prognostic analysis.

Results: ERCC1-positive expression was statistically significant in the older patients (P = 0.032). In the multivariate analysis, the prognostic factors for DFS were female sex (P = 0.016), N stage (P = 0.009), and postoperative carcinoembryonic antigen level (P = 0.001), but ERCC1 expression was not a statistically significant prognostic factor for DFS in the univariate analysis (P = 0.397). The 5-year DFS rate was not significantly associated with the ERCC1 expression in all patients (P = 0.396) or with stage III disease (P = 0.582).

Conclusion: We found that ERCC1 expression was not significantly correlated with the 5-year DFS as reflected by the oncologic outcomes in patients with high-risk stages II and III colon cancer treated with FOLFOX adjuvant chemotherapy.

No MeSH data available.


Related in: MedlinePlus